Home » Medical Devices » Anemia Treatment Drugs Market

Anemia Treatment Drugs Market By Type Of Anemia (Iron Deficiency Anemia, Thalassemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia, Pernicious Anemia), By Type Of Drug (Supplements, Antibiotics, Immunosuppresants, Bone Marrow Stimulants, Corticosteroids, Gene Therapy, Iron Chelating Agents) – Growth, Future Prospects And Competitive Landscape, 2018 – 2026

Name: Anemia Treatment Drugs Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2019-02-27
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Anemia Treatment Drugs Market

Summary
Table Of Content
Request Sample

Industry Outlook

The anemia treatment drugs market accounted for a market value of US$ 23,155.8 million in 2017 and is projected to grow at a CAGR of 16.4% during the forecast period from 2018 to 2026. An abnormal decrease in the level of red blood cells, irregular red blood cell morphology, or inadequate concentration of hemoglobin in the blood results in anemia. Anemia is also caused by numerous nutritional and non-nutritional factors, such as infectious diseases (including malaria, soil-transmitted helminthiasis, hookworm, and tuberculosis). The World Health Organization (WHO) estimated that globally, anemia prevalence averaged 56%, with geographical variations in Europe and Asia, where the prevalence is in a range of 35% to 75%.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Synopsis

The presence of more than five molecules in clinical trials phase III owned by large pharmaceutical companies is expected to drive significant growth in the sickle cell anemia market in the coming years.

During the forecast period from 2018 to 2026, sickle cell anemia will grow at an exponential rate due to rising prevalence and awareness related to sickle cell anemia and the expected market entry of monoclonal antibodies and other biological drugs to treat sickle cell anemia efficiently. According to the World Health Organization (WHO), it is estimated that 312,000 children will be born worldwide with sickle cell anemia annually. Globally, the greatest burden exists in Sub-Saharan Africa, where 75% of the world’s sickle cell disease occurs. However, the three major molecules targeting sickle cell anemia in clinical trial phase III are Rivipansel (Pfizer, Inc.), Voxelotor (Global Blood Therapeutics, Inc.), and GBT440 (Global Blood Therapeutics, Inc.). Thus, market approval of these drugs in the near future will assist the overall growth of the sickle cell anemia treatment market.

With the highest prevalence of the anemic population and increasing awareness about the diagnosis and treatment of anemia, Asia Pacific is expected to be the fastest-growing region in the global anemia treatment drugs market.

During the forecast period from 2018 to 2026, Asia-Pacific is expected to grow significantly due to rising prevalence and awareness related to anemia, the initiation of anemia awareness campaigns by government and non-government organizations, and the development of economic and healthcare infrastructure. According to the Sickle Cell Disease Coalition (SCDC), in 2016, India set a world record for screening 7.5 million people for SCD in a single day with the help of effective awareness campaigns carried out by both government and non-government organizations. The most significant development in Asia-Pacific was associated with advancements in screening, interventions, skilled healthcare providers, and medication accessibility. The strong drug pipeline for anemia treatment is also considered one of the key factors expected to assist the growth of the Asia-Pacific anemia treatment drugs market in the near future.

Periods of History and Forecast

The anemia treatment drugs market was analyzed considering current market trends for the base year of 2017, and based on future trends, CAGRs were calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report on the anemia treatment drugs market provides detailed information related to market dynamics, such as restraints, drivers, and opportunities, along with global trends. The report provides a broad summary of the global anemia treatment drugs market by segmenting the market based on anemia type, drug type, and geography. The objective of publishing this in-depth research report is to assist industry stakeholders in carrying out strategic decisions and implementation in the anemia treatment drugs market.

This report further describes the major qualitative assessment factors, including key market trends, market drivers, and market restraints, to assist in a better understanding of the global anemia treatment drugs market. The major players were analyzed based on their product offerings, market strategies, recent developments, and business strengths. The report also provides an attractive investment proposition based on the exhaustive geographical research carried out based on PESTEL analysis. Major companies profiled in the report include Pfizer, Inc., Amgen, Inc., Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen Pharmaceuticals, Bayer AG, AMAG Pharmaceuticals, GlaxoSmithKline plc, Akebia Therapeutics, Vifor Pharma Management, Ltd., and FibroGen, Inc., among others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

What are anemia treatment drugs, and how are they used to treat different types of anemia?
Which type of anemia is the largest segment in the global anemia treatment drug market?
What are the recent market trends and growth opportunities for the companies operating in the anemia treatment industry?
Which are the most attractive markets geographically for anemia treatment technology?
What are the pipeline analysis and overall future scenarios of the anemia treatment drug market?
What is the competitive landscape of the anemia treatment drug market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global ATD Market Portraiture
2.2. Global ATD Market, by Type of Anemia, 2017 (US$ Mn)
2.3. Global ATD Market, by Type of Drug, 2017 (US$ Mn)
2.4. Global ATD Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Anemia Treatment Drugs (ATD) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Rising prevalence of anemia and complications related with diseases related to anemia
3.2.2. Increasing awareness related to anemia diagnosis and treatment especially in developing and under developed countries from Asia, Africa & South America
3.3. Challenges
3.3.1. Chronic anemia is treated with bone marrow transplantation or blood transfusion there no drug treatment available in the market
3.4. Opportunities
3.4.1. Strong pipeline with number of promising molecules that will drive the overall ATD market in the near future
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Anemia Treatment Drugs (ATD) Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Iron deficiency anemia
4.3. Thalassemia
4.4. Aplastic anemia
4.5. Hemolytic anemia
4.6. Sickle cell anemia
4.7. Pernicious anemia

Chapter 5. Global Anemia Treatment Drugs (ATD) Market, by Type of Drug, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Supplements
5.3. Antibiotics
5.4. Immunosuppresants
5.5. Bone Marrow Stimulants
5.6. Corticosteroids
5.7. Gene Therapy
5.8. Iron Chelating Agents
5.9. Pipeline Analysis: Global ATD Market
5.9.1. Overview
5.9.2. Phase III Drugs: Market Size Forecast till 2026 (US$ Mn)
5.9.2.1. FG-4592/Roxadustat (FibroGen)
5.9.2.2. Daprodustat/GSK1278863 (GlaxoSmithKline)
5.9.2.3. Molidustat/BAY85-3934 (Bayer)
5.9.2.4. MT-6548 (Mitsubishi Tanabe Pharma Corporation)
5.9.2.5. Rivipansel/GMI-1070 (Pfizer)
5.9.2.6. Luspatercept (Celgene)
5.9.2.7. AG-348 (Agios Pharmaceuticals, Inc.)
5.9.2.8. Sutimlimab (Bioverativ Therapeutics Inc.)
5.9.2.9. V114 (Merck Sharp & Dohme Corp.)
5.9.2.10. LentiGlobin/BB305 (bluebird bio)
5.9.2.11. APL-2 (Apellis Pharmaceuticals, Inc.)
5.9.2.12. ALXN1210 (Alexion Pharmaceuticals)
5.9.2.13. OMS721 (Omeros Corporation)
5.9.3. Phase II (Tabular Representation)
5.9.4. Phase I (Tabular Representation)

Chapter 6. Global Anemia Treatment Drugs (ATD) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America ATD Market Analysis, 2016 – 2026
6.2.1. North America ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.2.2. North America ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.2.3. North America ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe ATD Market Analysis, 2016 – 2026
6.3.1. Europe ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.3.2. Europe ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.3.3. Europe ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific ATD Market Analysis, 2016 – 2026
6.4.1. Asia Pacific ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.4.3. Asia Pacific ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of APAC
6.5. Latin America ATD Market Analysis, 2016 – 2026
6.5.1. Latin America ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.5.2. Latin America ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.5.3. Latin America ATD Market, by Country, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) ATD Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa ATD Market, by Type of Anemia, 2016–2026 (US$ Mn)
6.6.2. Middle East & Africa ATD Market, by Type of Drug, 2016–2026 (US$ Mn)
6.6.3. MEA ATD Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Hoffmann-La Roche Ltd.
7.3. Novartis AG
7.4. Pfizer, Inc.
7.5. Janssen Pharmaceuticals, Inc.
7.6. Teva Pharmaceutical Industries, Ltd.
7.7. AMAG Pharmaceuticals
7.8. Rockwell Medical
7.9. Akebia Therapeutics
7.10. Vifor Pharma Management, Ltd.
7.11. FibroGen, Inc.
7.12. GlaxoSmithKline plc
7.13. Bayer AG
7.14. Omeros Corporation
7.15. Merck Sharp & Dohme Corp.

List of Figures

FIG. 1 Anemia Treatment Drugs (ATD): Market Segmentation
FIG. 2 Global ATD Market Share, by Type of Anemia, 2017 (US$ Mn)
FIG. 3 Global ATD Market Share, by Type of Drug, 2017 (US$ Mn)
FIG. 4 Global ATD Market, by Geography, 2017 Vs 2026 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Market Competition Landscape, by Key Players, 2017
FIG. 7 Global Iron Deficiency ATD Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Thalassemia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Aplastic ATD Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Hemolytic ATD Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Sickle Cell ATD Market, 2016 – 2026 (US$ Mn)
FIG. 12 Global Pernicious ATD Market, 2016 – 2026 (US$ Mn)
FIG. 13 Global Supplements Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 14 Global Antibiotics Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 15 Global Immunosuppressant Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 16 Global Bone Marrow Stimulants Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 17 Global Corticosteroids Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 18 Global Gene Therapy Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 19 Global Iron Chelating Agents Market for Anemia Treatment, 2016 – 2026 (US$ Mn)
FIG. 20 U.S. ATD Market, 2016 – 2026 (US$ Mn)
FIG. 21 Canada ATD Market, 2016 – 2026 (US$ Mn)
FIG. 22 U.K. ATD Market, 2016 – 2026 (US$ Mn)
FIG. 23 Germany ATD Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest Of Europe ATD Market, 2016 – 2026 (US$ Mn)
FIG. 25 Japan ATD Market, 2016 – 2026 (US$ Mn)
FIG. 26 China ATD Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest Of Asia Pacific ATD Market, 2016 – 2026 (US$ Mn)
FIG. 28 Brazil ATD Market, 2016 – 2026 (US$ Mn)
FIG. 29 Mexico ATD Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest Of Latin America ATD Market, 2016 – 2026 (US$ Mn)
FIG. 31 GCC ATD Market, 2016 – 2026 (US$ Mn)
FIG. 32 Rest Of Middle East And Africa ATD Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Anemia Treatment Drugs (ATD) Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 2 Global ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 3 North America ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 4 North America ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 5 North America ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 6 Europe ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 7 Europe ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 8 Europe ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America ATD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Middle East & Africa ATD Market, by Type of Anemia, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East & Africa ATD Market, by Type of Drug, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East And Africa ATD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 18 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Janssen Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 AMAG Pharmaceuticals : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Rockwell Medical : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Akebia Therapeutics : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Vifor Pharma Management, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 FibroGen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Omeros Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Merck Sharp & Dohme Corp. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions:

What is the size of Anemia Treatment Drugs Market?

The market for Anemia Treatment Drugs is expected to reach US$ 23,155.8 Mn in 2026.

What is the Anemia Treatment Drugs Market CAGR?

The Anemia Treatment Drugs market is expected to see significant CAGR growth over the coming years, at 16.4%.

What is the Forecast period considered for Anemia Treatment Drugs Market?

The report is forecasted from 2018-2026.

What is the base year considered for Anemia Treatment Drugs Market?

The base year of this report is 2017.

Who are the major players in this market?

Amgen, Inc.,Hoffmann-La Roche Ltd.,Novartis AG,Pfizer, Inc.,Janssen Pharmaceuticals, Inc. are some of the major players in the global market

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Chemotherapy Induced Anemia Market

The Chemotherapy-Induced Anemia Market is expected to grow from USD 2,262 million in 2024 to USD 4,094.66 million by 2032, reflecting a compound annual growth rate (CAGR) of 7.7%.

Warm Autoimmune Hemolytic Anemia Treatment Market

The Warm Autoimmune Hemolytic Anemia Treatment Market is projected to grow from USD 580 million in 2024 to an estimated USD 1225.31 million by 2032, with a compound annual growth rate (CAGR) of 9.8% from 2024 to 2032.

Iron Deficiency Anemia Treatment Market

The Iron Deficiency Anemia Treatment Market is valued at approximately USD 12,110 million and is projected to grow at a compound annual growth rate (CAGR) of 8.30%, reaching around USD 22,917.74 million by 2032.

Drug-Induced Immune Hemolytic Anemia Market

The global Drug-induced immune hemolytic anemia market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 5.90% between 2023 and 2030.

Ferrous Gluconate Market

The Global Ferrous Gluconate Market is projected to grow from USD 452 million in 2024 to an estimated USD 709 million based on 2032, with a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032.

Active Iron Supplement Market

Active Iron Supplement Market size was valued at USD 1,120.10 million in 2018, reached USD 1,607.72 million in 2024, and is anticipated to reach USD 2,569.55 million by 2032, at a CAGR of 5.62% during the forecast period.

Iron Supplements Market

The Iron Supplements Market size was valued at USD 2,543.74 million in 2018, reached USD 3,356.32 million in 2024, and is anticipated to reach USD 4,760.79 million by 2032, at a CAGR of 4.16% during the forecast period.

Oral Iron Supplements Market

Oral Iron Supplements Market size was valued USD 2,521.65 Million in 2024 and is anticipated to reach USD 4,128.06 Million by 2032, at a CAGR of 6.33% during the forecast period.

Erythropoietin Stimulating Agents Market

Erythropoietin Stimulating Agents Market size was valued at USD 15225.15 million in 2024 and is anticipated to reach USD 29762.9 million by 2032, at a CAGR of 8.74% during the forecast period (2024-2032).

Urology Devices Market

The Urology Devices Market size was valued at USD 26,300.0 million in 2018 to USD 34,059.0 million in 2024 and is anticipated to reach USD 60,058.8 million by 2032, at a CAGR of 7.4% during the forecast period.

Urology Imaging Systems Market

The Urology Imaging Systems Market size was valued at USD 380.0 million in 2018 to USD 427.9 million in 2024 and is anticipated to reach USD 585.2 million by 2032, at a CAGR of 4.0% during the forecast period.

Epigenetics Diagnostics Market

The epigenetics diagnostics market size was valued at USD 19302 million in 2024 and is anticipated to reach USD 62412.4 million by 2032, at a CAGR of 15.8 % during the forecast period (2024-2032).

Handheld Echocardiography Devices Market

The Handheld Echocardiography Devices Market was valued at USD 3,251.1 million in 2024 and is projected to reach USD 4,623.4 million by 2032, reflecting a CAGR of 4.5% during the forecast period.

Endoscope Reprocessing Market

The Endoscope Reprocessing Market was valued at USD 3,190.5 million in 2024 and is projected to reach USD 6,357.2 million by 2032, registering a CAGR of 9% during the forecast period.

Concentrator Devices Market

The Global Concentrator Devices Market size was valued at USD 1,426.83 million in 2018 to USD 2,414.14 million in 2024 and is anticipated to reach USD 5,018.71 million by 2032, at a CAGR of 8.92% during the forecast period.

Stent Retriever Market

Stent Retriever Market size was valued at USD 2605.4 million in 2024 and is anticipated to reach USD 5424.5 million by 2032, at a CAGR of 9.6% during the forecast period.

ENT Workstation Market

The ent workstation market size was valued at USD 63774.9 million in 2024 and is anticipated to reach USD 112897.4 million by 2032, at a CAGR of 7.4 % during the forecast period (2024-2032).

Endovascular Treatment Devices Market

Endovascular Treatment Devices Market size was USD 3,480.5 million in 2024 and is projected to reach USD 7,037.5 million by 2032, registering a CAGR of 9.2% during the forecast period.

Endoscopic Stricture Management Device Market

Endoscopic Stricture Management Device Market size was valued at USD 1490.5 million in 2024 and is anticipated to reach USD 2357.7 million by 2032, at a CAGR of 5.9% during the forecast period.

Endometriosis Treatment Market

The Endometriosis Treatment Market size was valued at USD 1640.5 million in 2024 and is anticipated to reach USD 4061.8 million by 2032, growing at a CAGR of 12% during the forecast period.

Endomyocardial Biopsy Market

Endomyocardial Biopsy Market size was valued at USD 355.8 million in 2024 and is anticipated to reach USD 611.3 million by 2032, at a CAGR of 7% during the forecast period.

Purchase Options

Single User

$4999

Multi User

$6999

Enterprise

$12999

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert